The month ahead: May’s remaining events
Conference activity picks up, with the big one – ASCO – at the end of the month.
Conference activity picks up, with the big one – ASCO – at the end of the month.
Golcadomide will begin a new pivotal trial in follicular lymphoma.
The company buys Belgium’s EsoBiotec for $425m.
J&J decides not to opt in to erzotabart, and Genmab pulls the plug.
Fianlimab NSCLC data are delayed, while odronextamab gets a DLBCL blow.